Report Publication Announcement • Jan 31, 2022
Report Publication Announcement
Open in ViewerOpens in native device viewer
Press Release
Toulouse, FRANCE, Lakeland MI, UNITED-STATES, January 31, 2022, 5:45 pm CET ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2022.
| Events | Date* |
|---|---|
| Cash position and activity update for Q4 2021 | February 24, 2022 |
| 2021 Annual Results | April 28, 2022 |
| Cash position and activity update for Q1 2022 | May 19, 2022 |
| Cash position and activity update for Q2 2022 | August 18, 2022 |
| 2022 Half Year Results | September 29, 2022 |
| Cash position and activity update for Q3 2022 | November 17, 2022 |
* indicative dates subject to change
ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.
| NewCap | NewCap |
|---|---|
| Investor relations | Media relations |
| Louis-Victor Delouvrier | Nicolas Merigeau |
| [email protected] | [email protected] |
| +33 (0)1 44 71 98 53 | +33 (0)1 44 71 94 98 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.